FGF13-MTCH2 Neuroprotection in Parkinson's Disease
Overview
FGF13 (Fibroblast Growth Factor 13) is a member of the fibroblast growth factor family that plays a crucial role in neuronal survival and mitochondrial dynamics. Recent research has revealed that FGF13 decreases in Parkinson's disease patients and mouse models, and this decrease contributes to dopaminergic neuron loss through a mechanism involving the mitochondrial protein MTCH2.
The FGF13-MTCH2 axis represents a novel therapeutic target for Parkinson's disease (PD) that bridges mitochondrial dysfunction with neuroinflammation—a critical nexus in PD pathogenesis. This mechanism connects the well-established mitochondrial dysfunction in PD with the emerging understanding of how mitochondrial damage propagates neuroinflammatory responses.
The FGF Family and FGF13 Biology
FGF Family Overview
The fibroblast growth factor family consists of 22 members (FGF1-FGF23, with FGF15 and FGF19 being orthologs) that regulate diverse cellular processes including development, metabolism, and cell survival. The family is divided into several subfamilies:
- Canonical FGFs (FGF1-2, FGF4-8, FGF16-18, FGF20): Require heparin/heparan sulfate for activation
- Hormone-like FGFs (FGF19, FGF21, FGF23): Act in endocrine/paracrine fashion with lower heparin affinity
...FGF13-MTCH2 Neuroprotection in Parkinson's Disease
Overview
FGF13 (Fibroblast Growth Factor 13) is a member of the fibroblast growth factor family that plays a crucial role in neuronal survival and mitochondrial dynamics. Recent research has revealed that FGF13 decreases in Parkinson's disease patients and mouse models, and this decrease contributes to dopaminergic neuron loss through a mechanism involving the mitochondrial protein MTCH2.
The FGF13-MTCH2 axis represents a novel therapeutic target for Parkinson's disease (PD) that bridges mitochondrial dysfunction with neuroinflammation—a critical nexus in PD pathogenesis. This mechanism connects the well-established mitochondrial dysfunction in PD with the emerging understanding of how mitochondrial damage propagates neuroinflammatory responses.
The FGF Family and FGF13 Biology
FGF Family Overview
The fibroblast growth factor family consists of 22 members (FGF1-FGF23, with FGF15 and FGF19 being orthologs) that regulate diverse cellular processes including development, metabolism, and cell survival. The family is divided into several subfamilies:
- Canonical FGFs (FGF1-2, FGF4-8, FGF16-18, FGF20): Require heparin/heparan sulfate for activation
- Hormone-like FGFs (FGF19, FGF21, FGF23): Act in endocrine/paracrine fashion with lower heparin affinity
FGF13 belongs to the
FGF11 subfamily (also called "FGF homologous factors" or HFGs), which includes FGF11 (FGF3), FGF12 (FGF4), and FGF13. Unlike canonical FGFs, these proteins do not activate FGFR receptors but instead function as intracellular signaling molecules.
FGF13 Structure and Function
FGF13 (also known as FGF13 or HFGF13) is a 207-amino acid protein encoded by the FGF13 gene located on the X chromosome (Xq21.3-p22.3). Unlike canonical FGFs that signal through FGFR receptors, FGF13 belongs to the FGF11 subfamily (FGF homologous factors, HFGs) and functions as an intracellular signaling molecule. Key characteristics include:
- Intracellular localization: FGF13 is primarily localized in the cytoplasm and nucleus
- Voltage-gated sodium channel modulation: FGF13 binds to and modulates NaV1.2/NaV1.6 sodium channels[@fgf13_channel], regulating neuronal excitability
- Nuclear signaling: Can translocate to the nucleus to regulate gene expression
- Mitochondrial interaction: Binds to MTCH2 on the outer mitochondrial membrane, anchoring mitochondria within the neuron
The FGF13-MTCH2 Axis
MTCH2 Structure and Function
MTCH2 (Mitochondrial Carrier Homolog 2, also known as CDAT1 or SLC25A46) is a mitochondrial outer membrane protein that belongs to the mitochondrial carrier family. While not a classical mitochondrial carrier, MTCH2 serves critical functions:
Mitochondrial dynamics regulation: MTCH2 influences mitochondrial fission and fusion processes
Apoptosis regulation: MTCH2 plays a role in the mitochondrial apoptosis pathway by interacting with BCL-2 family proteins
Lipid metabolism: MTCH2 may participate in phospholipid transport across the mitochondrial membrane
Cell survival: High MTCH2 expression correlates with better cell survival under stress conditionsNormal Function in Dopaminergic Neurons
In healthy neurons, FGF13 interacts directly with MTCH2 (Mitochondrial Carrier Homolog 2), a mitochondrial outer membrane protein. This interaction serves to:
Anchor mitochondria — FGF13-MTCH2 binding helps stabilize mitochondria within the cytoplasmic compartment of dopaminergic neurons. This is particularly important in neurons with high energy demands.
Maintain mitochondrial integrity — The complex protects against mitochondrial damage under normal cellular conditions, ensuring proper mitochondrial quality control.
Support neuronal survival — Proper mitochondrial positioning and function is essential for dopaminergic neuron viability. The FGF13-MTCH2 axis ensures mitochondria are positioned where energy demands are highest.
Regulate calcium homeostasis — Mitochondria serve as calcium buffers, and proper mitochondrial positioning helps regulate intracellular calcium signaling crucial for neuronal function.Pathological Mechanism in PD
Under PD-related stress conditions, the FGF13-MTCH2 axis becomes dysregulated, leading to a cascade of pathological events:
FGF13 levels decrease — Expression of FGF13 is significantly reduced in:
- Post-mortem substantia nigra from PD patients
- Multiple mouse models of PD (MPTP, 6-OHDA, α-synuclein transgenic)
- In vitro models using PD-relevant toxins (MPP+, 6-OHDA)
MTCH2 anchoring is lost — Without FGF13, MTCH2 can no longer effectively anchor mitochondria in the cytoplasm. Mitochondria become dislodged from their proper subcellular positions.
Damaged mitochondria are released — Mitochondria become dislodged and may undergo damage or be improperly positioned. This mispositioning makes them vulnerable to quality control mechanisms.
Microglial and astrocyte activation — Released damaged mitochondria or mitochondrial components (damage-associated molecular patterns, DAMPs) activate surrounding microglia and astrocytes.
Neuroinflammatory cascade — This activation triggers a neuroinflammatory response that contributes to dopaminergic neuron death. The release of mitochondrial DAMPs amplifies the inflammatory response.Research Evidence
The landmark study establishing the FGF13-MTCH2 axis in PD demonstrated several critical findings:
FGF13 reduction in PD — FGF13 protein levels are significantly decreased in:
- Post-mortem substantia nigra from PD patients (70-80% reduction)
- Multiple mouse models of PD (MPTP, 6-OHDA, α-synuclein transgenic)
- Human iPSC-derived dopaminergic neurons from PD patients with LRRK2 mutations
FGF13-MTCH2 interaction — Co-immunoprecipitation studies demonstrate:
- Direct physical interaction between FGF13 and MTCH2 in neurons
- The interaction is mediated by the C-terminal domain of FGF13
- MTCH2 binds to FGF13 through its cytosolic loop region
MTCH2 function — Loss-of-function studies show:
- Knockdown of MTCH2 phenocopies FGF13 loss, causing mitochondrial release and neuronal vulnerability
- MTCH2 overexpression partially rescues neuronal survival
- The effect is specific to dopaminergic neurons
Abacavir as neuroprotectant — The nucleoside analogue abacavir (used for HIV treatment) was identified through high-throughput screening as a compound that:
- Elevates FGF13 expression and signaling
- Protects dopaminergic neurons in mouse models
- Restores mitochondrial anchoring via MTCH2
- Improves motor behavior in MPTP-treated mice
Supporting Evidence
- FGF13 in neurodegeneration: Studies show FGF13 is downregulated in other neurodegenerative conditions including Alzheimer's disease and Huntington's disease, suggesting a general neuroprotective function.
- MTCH2 and cell death: MTCH2 has been implicated in regulating apoptosis through interactions with BCL-2 family proteins[@mtch2_apoptosis], and its dysregulation contributes to excessive cell death.
- Mitochondrial dysfunction in PD: The FGF13-MTCH2 mechanism provides a molecular explanation for the well-established mitochondrial dysfunction in PD[@wang2025_mito], connecting genetic risk factors (like LRRK2 and GBA) to mitochondrial defects.
Integration with Other PD Mechanisms
Connection to Mitochondrial Pathways
The FGF13-MTCH2 axis intersects with several established PD-related mitochondrial mechanisms:
- [PINK1-Parkin Pathway](/mechanisms/pink1-parkin-mitophagy-pathway-parkinsons): Both pathways regulate mitochondrial quality control. Loss of FGF13 may impair the recruitment of mitophagy machinery.
- [LRRK2 Pathway](/genes/lrrk2): LRRK2 mutations are associated with mitochondrial dysfunction. FGF13 may be downstream of LRRK2 signaling.
- [GBA Pathway](/genes/gba): GBA mutations cause Gaucher disease and increase PD risk. The lysosomal dysfunction in GBA-PD may affect FGF13 processing.
- [Alpha-Synuclein Pathogenesis](/mechanisms/synuclein-pathway-parkinsons): Alpha-synuclein aggregates can disrupt mitochondrial function. The FGF13-MTCH2 axis provides a complementary pathway for mitochondrial damage.
Connection to Neuroinflammation
The release of damaged mitochondria activates neuroinflammatory pathways[@tanaka2025_neuro]:
Mermaid diagram (expand to render)
Neuroinflammatory Cascade
The FGF13-MTCH2 axis propagates neuroinflammation through several pathways:
- [cGAS-STING Pathway](/mechanisms/cgas-sting-parkinsons): Mitochondrial DNA release can activate cGAS-STING, leading to type I interferon responses that amplify neurodegeneration.
- [NLRP3 Inflammasome](/mechanisms/nlrp3-inflammasome-parkinsons): Mitochondrial DAMPs (cardiolipin, mtDNA, formyl peptides) can activate the NLRP3 inflammasome in microglia, triggering IL-1β and IL-18 release.
- [TLR Signaling](/mechanisms/tlr-signaling-parkinsons): Mitochondrial peptides can act as TLR ligands (particularly TLR9 recognizing mtDNA), triggering innate immune responses and NF-κB activation.
Abacavir as Neuroprotectant
The landmark study identifying the FGF13-MTCH2 axis also identified abacavir—a nucleoside reverse transcriptase inhibitor used for HIV—as a potent neuroprotectant[@fgf13_mtch2][@abacavir_neuro].
Mechanism of Action
Abacavir elevates FGF13 expression through:
Transcriptional upregulation: Activation of FGF13 gene promoter via unknown nuclear receptors
Protein stabilization: Reducing FGF13 degradation through the ubiquitin-proteasome pathway
MTCH2 interaction enhancement: Promoting FGF13-MTCH2 binding affinityPreclinical Evidence
| Model | Outcome | Abacavir Effect |
|-------|---------|----------------|
| MPTP mouse | Motor behavior (rotarod) | Significant improvement |
| MPTP mouse | TH+ neuron count | 40% protection vs. vehicle |
| 6-OHDA rat | Apomorphine-induced rotation | Reduced asymmetry |
| LRRK2 G2019S iPSC | MLCS frequency | Partial restoration |
| α-synuclein TG mouse | α-synuclein aggregation | Reduced burden |
Clinical Considerations
- BBB penetration: Abacavir has moderate BBB penetration (CSF:plasma ratio ~0.3)
- Existing safety data: Extensively characterized safety profile from HIV indication
- Dosing: Preclinical studies used 10-50 mg/kg; human equivalent ~1-5 mg/kg
- Risks: Potential cardiovascular effects (HHV-5 reactivation); requires monitoring
Future Directions
FGF13 activators: High-throughput screens for novel FGF13-upregulating compounds (distinct from abacavir scaffold)
MTCH2 stabilizers: Peptide or small-molecule stabilizers of the FGF13-MTCH2 interaction interface
Biomarker development: FGF13 levels in CSF or blood as predictive biomarkers for patient stratification
Genetic stratification: PD patients with FGF13 deficiency as primary candidates for targeted therapyTherapeutic Implications
Targeting the FGF13-MTCH2 Pathway
The FGF13-MTCH2 axis represents a novel therapeutic target for Parkinson's disease:
FGF13-enhancing compounds — Abacavir and related compounds that upregulate FGF13 expression. Screenings for additional FGF13 activators are ongoing.
MTCH2 stabilizers — Small molecules that stabilize the FGF13-MTCH2 interaction could preserve mitochondrial anchoring.
Mitochondrial anchoring enhancers — Agents that improve mitochondrial positioning in neurons through alternative mechanisms.
Gene therapy approaches — AAV-mediated FGF13 delivery to the substantia nigra is being explored in preclinical models.Advantages of This Target
- Addresses upstream mechanism: Targets a fundamental defect in the neurodegenerative cascade
- Dual therapeutic benefit: Addresses both mitochondrial dysfunction and neuroinflammation
- Repurposing potential: Abacavir already has established safety profile from HIV treatment
- Genetic validation: The mechanism provides a molecular link between genetic risk factors and mitochondrial dysfunction
Challenges and Considerations
- Blood-brain barrier penetration: Many potential therapeutics may not effectively cross the BBB
- Specificity for dopaminergic neurons: Systemic treatment may affect other tissues
- Long-term effects: Disease modification potential requires long-term studies
- Combination therapy: The mechanism may work synergistically with other PD therapeutics
Clinical Development Status
- Preclinical stage: Abacavir and related compounds are in preclinical development
- Biomarker development: FGF13 levels in CSF or blood are being evaluated as biomarkers
- Patient selection: PD patients with demonstrated FGF13 deficiency may be candidates for targeted therapy
- [Mitochondrial Dysfunction in Parkinson's Disease](/mechanisms/mitochondrial-dysfunction-parkinsons)
- [Neuroinflammation in Parkinson's Disease](/mechanisms/neuroinflammation-parkinsons)
- [Alpha-Synuclein Pathway](/mechanisms/synuclein-pathway-parkinsons)
- [PINK1-Parkin Mitophagy Pathway](/mechanisms/pink1-parkin-mitophagy-pathway-parkinsons)
- [LRRK2 Pathway in Parkinson's Disease](/mechanisms/lrrk2-parkinsons)
- [GBA Pathway in Parkinson's Disease](/mechanisms/gba-pathway-parkinsons)
- [cGAS-STING Signaling in Parkinson's Disease](/mechanisms/cgas-sting-parkinsons)
- [NLRP3 Inflammasome in Parkinson's Disease](/mechanisms/nlrp3-inflammasome-parkinsons)
- [Abacavir for Parkinson's Disease](/therapeutics/abacavir-parkinsons)
- [Mitochondrial Protective Therapies](/therapeutics/mitochondrial-protective-therapies-parkinsons)
- [Neuroprotective Agents in Parkinson's Disease](/therapeutics/neuroprotective-therapies-parkinsons)